Corrigendum

Corrigendum to “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites”

Jasmohan S. Bajaj,1 James H. Fischer,2 Patrick Yeramian,3 Edith A. Gavis,4 Andrew Fagan,4 Paolo Angeli,5 Guadalupe Garcia-Tsao,6 Jonathan M. Adams,3 and Penelope Markham3

1Central Virginia Veterans Healthcare System and Virginia Commonwealth University, Medical Center, Richmond VA, USA
2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
3BioVie, Inc., Santa Monica, CA, USA
4Central Virginia Veterans Healthcare System, Richmond, VA, USA
5Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, University of Padova, Italy
6Digestive Diseases Section, Yale University School of Medicine, VA-CT Healthcare System, New Haven/West Haven, CT, USA

Received 3 November 2022; Accepted 3 November 2022; Published 6 February 2023

Copyright © 2023 Jasmohan S. Bajaj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites” [1], there was an error in the Conflicts of Interest section, where Jasmohan S. Bajaj was incorrectly listed as an employee of BioVie, Inc. Additionally, some additional information was omitted in error. The corrected section appears in the following:

Conflicts of Interest

JF and PY are consultants who received compensation from BioVie. EG and AF received none. PA is a clinical advisor who received honorarium from BioVie and from Grifols. GG-T is a clinical advisor who received honorarium from BioVie. JSB received grant support to his institution from BioVie. JA and PM are BioVie employees.

References